跳轉至內容
Merck
  • Genetic manipulation of the ghrelin signaling system in male mice reveals bone compartment specificity of acylated and unacylated ghrelin in the regulation of bone remodeling.

Genetic manipulation of the ghrelin signaling system in male mice reveals bone compartment specificity of acylated and unacylated ghrelin in the regulation of bone remodeling.

Endocrinology (2014-07-26)
Patric J D Delhanty, Martijn van der Velde, Bram C J van der Eerden, Yuxiang Sun, Julia M M Geminn, Aart-Jan van der Lely, Roy G Smith, Johannes P T M van Leeuwen
摘要

Ghrelin receptor-deficient (Ghsr-/-) mice that lack acylated ghrelin (AG) signaling retain a metabolic response to unacylated ghrelin (UAG). Recently, we showed that Ghsr-deficiency affects bone metabolism. The aim of this study was to further establish the impact of AG and UAG on bone metabolism. We compared bone metabolism in Ghsr-/- (lacking only AG signaling) and ghrelin-deficient (Ghrl-/-; both AG and UAG deficient) male mice. Ghrl-/- mice had lower cortical bone mass, whereas Ghsr-/- mice had lower trabecular bone mass. This demonstrates bone compartment-specific effects of AG and a role for UAG in bone metabolism. Also, Ghrl-/- but not Ghsr-/- mice had increased bone formation rate and increased osteogenic stem cell numbers in their bone marrow. In ex vivo bone marrow cultures both AG and UAG inhibited osteoblast differentiation. This indicated that bone resorption must be increased in these mice. Accordingly, osteoclastogenesis rate was faster in bone marrow cultures from Ghsr-/- and Ghrl-/- mice, and osteoclast formation was inhibited by AG signaling and partially suppressed by UAG. In osteoblast cultures, AG markedly induced osteoprotegerin gene expression and both peptides reduced RANKL/osteoprotegerin ratio. These data describe unique cell-type specific effects of AG and UAG within a single tissue, supporting a tight and complex control of bone formation and resorption as well as a link between nutrition and bone metabolism. The balance between AG and UAG actions in the bone marrow may lead to bone compartmental-specific effects.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
甲基丙烯酸甲酯, contains ≤30 ppm MEHQ as inhibitor, 99%
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
USP
抗坏血酸, United States Pharmacopeia (USP) Reference Standard
Supelco
L -抗坏血酸, analytical standard
Sigma-Aldrich
苏木精
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Supelco
维生素C, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
甲基丙烯酸甲酯, 99%, stabilized
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Sigma-Aldrich
苏木精, certified by the Biological Stain Commission
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
维生素C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
凝血酶受体激动剂, ≥97% (HPLC)
Sigma-Aldrich
L -抗坏血酸, tested according to Ph. Eur.
两性霉素 B, European Pharmacopoeia (EP) Reference Standard
Supelco
L -抗坏血酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
甲基丙烯酸甲酯, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L -抗坏血酸, Vetec, reagent grade, 99%